newsfilter
← Latest News
GlobeNewswire·

MHRA Grants Marketing Authorization for GBT's Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for